Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors

Gene Therapy

Volumn 15, Issue 24, 2008, Pages 1606-1617

  Appledorn, D M ^a   McBride, A ^a   Seregin, S ^a   Scott, J M ^a   Schuldt, N ^a   Kiang, A ^b   Godbehere, S ^a   Amalfitano, A ^a,b,c  

^a Michigan State University ^*  (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; GENE EXPRESSION; HUMORAL IMMUNITY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; THROMBOCYTOPENIA;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT FACTOR B; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; CYTOKINES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNITY, INNATE; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; TRANSDUCTION, GENETIC; TRANSGENES;

MIRIDAE; MUS;

EID: 57049106918     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.114     Document Type: Article

References (48)

1. Wu L, Kong WP, Nabel GJ. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 2005; 79: 8024-8031.
2. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408: 605-609.
3. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194: 1638-1649.
4. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006; 80: 1959-1964.
5. Molinier-Frenkel V, Gahery-Segard H, Mehtali M, Le Boulaire C, Ribault S, Boulanger P et al. Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74: 7678-7682.
6. Caetano BC, Bruna-Romero O, Fux B, Mendes EA, Penido ML, Gazzinelli RT. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther 2006; 17: 415-426.
7. Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, Parameswaran N et al. Adenovirus vector induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008 (in press).
8. Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Muller T, Pring-Akerblom P et al. Complement activation by recombinant adenoviruses. Gene Therapy 2001; 8: 1794-1800.
9. Hartman ZC, Black EP, Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the Toll-like receptor pathway in A549 cells. Virology 2007; 358 357-372.
10. Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 2007; 81: 1796-1812.
11. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 2004; 10: 1140-1142.
12. Kiang A, Hartman ZC, Everett RS, Serra D, Jiang H, Frank MM et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther 2006; 14: 588-598.
13. Barrington R, Zhang M, Fischer M, Carroll MC. The role of complement in inflammation and adaptive immunity. Immunol Rev 2001; 180: 5-15.
14. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991; 12: 322-326.
15. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: Biology and disease association. Mol Immunol 2001; 38: 133-149.
16. Kemper C, Atkinson JP. T-cell regulation: With complements from innate immunity. Nat Rev 2007; 7: 9-18.
17. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981-986.
18. Kiang A, Hartman ZC, Liao S, Xu F, Serra D, Palmer DJ et al. Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice. Mol Ther 2006; 13: 127-134.
19. Appledorn DM, Kiang A, McBride A, Jiang H, Seregin S, Scott JM et al Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Therapy 2008; 15: 885-901.
20. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B et al The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-8807.
21. Tibbles LA, Spurrell JC, Bowen GP, Liu Q, Lam M, Zaiss AK et al. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 2002; 76: 1559-1568.
22. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3 697-707.
23. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008; 105: 5483-5488.
24. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006; 108: 2554-2561.
25. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-7491.
26. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
27. Manickan E, Smith JS, Tian J, Eggerman TL, Lozier JN, Muller J et al Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 2006; 13: 108-117.
28. Wolins N, Lozier J, Eggerman TL, Jones E, Aguilar-Cordova E, Vostal JG. Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br J Haematol 2003; 123: 903-905.
29. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15: 378-385.
30. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007; 81: 3170-3180.
31. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157-1166.
32. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
33. Hawlisch H, Kohl J. Complement and Toll-like receptors: Key regulators of adaptive immune responses. Mol Immunol 2006; 43: 13-21.
34. Zhang X, Kimura Y, Fang C, Zhou L, Sfyroera G, Lambris JD et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007; 110: 228-236.
35. Helmy KY, Katschke Jr KJ, Gorgani NN, Kljavin NM, Elliott JM, Diehl L et al. CRIg: A macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006; 124: 915-927.
36. Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006; 444: 217-220.
37. Mehlhop E, Diamond MS. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 2006; 203: 1371-1381.
38. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol 2008; 82: 2727-2740.
39. Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 2008; 15: 499-505.
40. Hodges BL, Evans HK, Everett RS, Ding EY, Serra D, Amalfitano A. Adenovirus vectors with the 100 K gene deleted and their potential for multiple gene therapy applications. J Virol 2001; 75: 5913-5920.
41. Ng P, Graham FL. Construction of first-generation adenoviral vectors. Methods Mol Med 2002; 69: 389-414.
42. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
43. Everett RS, Hodges BL, Ding EY, Xu F, Serra D, Amalfitano A. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 2003; 14: 1715-1726.
44. Hu H, Serra D, Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999; 10: 355-364.
45. Hofstetter JR, Zhang A, Mayeda AR, Guscar T, Nurnberger Jr JI, Lahiri DK. Genomic DNA from mice: A comparison of recovery methods and tissue sources. Biochem Mol Med 1997; 62: 197-202.
46. Loniewski KJ, Patial S, Parameswaran N. Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages. Mol Immunol 2007; 44: 3715-3723.
47. Parameswaran N, Pao CS, Leonhard KS, Kang DS, Kratz M, Ley SC et al Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide- stimulated ERK1/2 activation in macrophages. J Biol Chem 2006; 281: 34159-34170.
48. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 2007; 15: 393-403.